Ten Bio News
A season of global engagement in skin science and innovation
This spring, Ten Bio joined leading voices in dermatology at events in France, the US, and Australia—spotlighting TenSkin™ as a powerful, human-relevant alternative to animal testing. From photoprotection to microneedle delivery, the message was clear: innovation needs better models.
Ten Bio joins James Hutton Institute’s Dundee campus to advance dermatological research
Ten Bio has officially joined the James Hutton Institute’s Dundee campus, marking a new chapter in its mission to advance human-relevant dermatology research. The move supports Ten Bio’s continued growth and fosters collaboration with one of Scotland’s leading scientific communities.
Predicting human response to gene-based therapies in preclinical evaluation
Why do so many gene therapies fail in clinical trials? A closer look at the preclinical gap—and how TenSkin™ is helping close it.
Beyond animal models: The future of skin testing is human-relevant and ready
As regulatory momentum builds and new human-relevant technologies emerge, the conversation is shifting. The question is no longer if we can replace animal testing in skin research — but how fast. This article explores why models like TenSkin™ offer a scalable, scientifically robust alternative that’s already reshaping preclinical research.
Setting the standard: How TenSkin is shaping regulatory change in skin testing
As regulators move away from animal testing, clear validation frameworks are needed to support alternatives. Explant models like TenSkin™ offer a human-relevant solution for preclinical skin research, improving predictability and reproducibility.
Pollution protection
Urban pollution drives demand for advanced skincare. Ten Bio’s TenSkin™ offers a next generation ex vivo model to test anti-pollution products, providing crucial insights that accelerate the development of scientifically validated, high-impact solutions.
Happy Holidays 2024
Spreading Holiday cheer – from the Ten Bio team to all of our clients, collaborators and partners – past, present and future! As the year winds down, we want to take a moment to express a heartfelt thank you for being a part of our journey through 2024.
The advantages of extended viability in TenSkin™ for dermatological research
Ten Bio’s TenSkin™ ex vivo human skin model offers two-week viability, enhancing the depth and reliability of skin studies, allowing for more detailed insights into skin health and treatment efficacy.
A tensioned human skin explant model used for preliminary assessment of chemexfoliant-stimulated bioeffects
Our latest study, using the TenSkinᵀᴹ model, demonstrates how our ex vivo platform is delivering biologically relevant insights into the effects of chemexfoliation (chemical peel) treatments on human skin.
Ten Bio shortlisted for The Courier Business Awards
We are proud to be announced as finalist in The Courier Business Awards in the Innovation and Technology category.
Converge Challenge prize for Ten Bio
Dr Hickerson was last night named runner-up in the Converge Challenge category of Converge 2020, receiving £29,000 in cash and in-kind business support. Converge is
Ten Bio launched from University of Dundee
Ten Bio launched from University of Dundee Researchers from the University of Dundee are looking to transform pharmaceutical and cosmetics testing with their spinout venture
Wounding response and wound healing in a novel tension-based skin explant model
This study highlights a tensioned ex vivo skin model that maintains viability and replicates in vivo wound healing. Improved keratin expression and 3D visualization confirm its value for studying biomarkers and testing therapies.
A tension-based skin explant model
This study introduces a tensioned ex vivo skin model that maintains viability, structural integrity, and physiological complexity. Unlike traditional models, it replicates in vivo responses, supports toxicity studies, and shows promise for dermatology research and drug discovery, reducing reliance on animal testing.